Pfizer reported positive Phase 2 results for its 25-valent pneumococcal conjugate vaccine, showing much stronger immune responses against serotype 3 compared to PREVNAR 20. The vaccine could cover up to 90% of disease-causing serotypes in children under five. Following these results, Pfizer launched a Phase 3 pediatric trial with up to 2,400 infants and plans to develop a 35-valent adult vaccine candidate by the end of 2026. This progress highlights Pfizer's commitment to expanding protection against pneumococcal disease in both children and adults.
Johnson & Johnson (JNJ) is seen as having a superior return and risk profile compared to Pfizer (PFE), mainly due to its consistent dividend growth over 63 years, lower payout ratio, ongoing share buybacks, and stable inventory levels. While Pfizer o...
More than 50 companies are actively developing over 55 new drugs for pulmonary arterial hypertension (PAH), a serious lung-related heart condition. These drugs are in various clinical trial stages, with several in late-stage development, aiming to im...
In May 2026, despite overall high market valuations, five stocks trading under $30 stand out for their strong financial health and growth prospects. Pfizer offers a 6.68% dividend yield and growth from its non-COVID portfolio and obesity pipeline, wh...
Stocks priced under $30 often get overlooked, but Pfizer and Nu Holdings stand out with solid balance sheets and growth potential. Pfizer, a global biopharma giant, trades around $25 with a strong dividend yield and promising pipeline despite some re...
Pfizer continues to be favored by investors due to its strong performance in the oncology drug market, highlighted by a 16.3% quarterly and 38.7% yearly sales increase of Padcev, driven by demand in combination with Merck's Keytruda. Despite recent F...
